Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer

  • Authors:
    • Seongeun Kang
    • Byungtak Kim
    • Sung-Bin Park
    • Gookjoo Jeong
    • Han-Sung Kang
    • Ran Liu
    • Sun Jung Kim
  • View Affiliations

  • Published online on: September 10, 2013     https://doi.org/10.3892/ijo.2013.2094
  • Pages: 1659-1665
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant hypermethylation of promoter regions in specific genes is a key event in the formation and progression of breast cancers, and an increasing number of marker genes have been identified. However, few genes which show methylation change in accordance with the progression of breast cancer have been identified. To identify genes which consistently undergo promoter methylation alterations as the tumor develops from a benign to a malignant form, genome-wide methylation databases of breast cancer cell lines from stage I to stage IV were analyzed. Heatmap and cluster analysis revealed that the genome-wide methylation changes showed a good accordance with tumor progression. Seven out of 14,495 genes were found to be consistently increased alongside the promoter methylation level through the normal cell line to the cancer stage IV cell lines. NEFL, one of the in silico hypermethylated genes in cancer, showed hypermethylation and lower expression in the cancer cell line MDA-MB-231, as well as in cancer tissues (methylation, p<0.05; expression, p<0.01). The expression was restored by inducing demethylation of the promoter in MDA-MB-231 cells. Our findings may lend credence to the possibility of using tumor stage-specific alterations in methylation patterns as biomarkers for estimating prognosis and assessing treatment options for breast cancer.
View Figures
View References

Related Articles

Journal Cover

November 2013
Volume 43 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kang S, Kim B, Park S, Jeong G, Kang H, Liu R and Kim SJ: Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer. Int J Oncol 43: 1659-1665, 2013.
APA
Kang, S., Kim, B., Park, S., Jeong, G., Kang, H., Liu, R., & Kim, S.J. (2013). Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer. International Journal of Oncology, 43, 1659-1665. https://doi.org/10.3892/ijo.2013.2094
MLA
Kang, S., Kim, B., Park, S., Jeong, G., Kang, H., Liu, R., Kim, S. J."Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer". International Journal of Oncology 43.5 (2013): 1659-1665.
Chicago
Kang, S., Kim, B., Park, S., Jeong, G., Kang, H., Liu, R., Kim, S. J."Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer". International Journal of Oncology 43, no. 5 (2013): 1659-1665. https://doi.org/10.3892/ijo.2013.2094